Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Effient | Prasugrel | Acute coronary syndrome | Do not list | Complete | ||
| Resotran | Prucalopride | Constipation, chronic | Do not list | Complete | ||
| Mozobil | Plerixafor | Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma | Do not list | Complete | ||
| Fampyra | Fampridine | Multiple sclerosis, improve walking disability | Do not list | Complete | ||
| Apprilon | Doxycycline monohydrate | Rosacea | Do not list | Complete | ||
| Latuda | Lurasidone | Schizophrenia | Do not list | Complete | ||
| Samsca | Tolvaptan | Hyponatremia, non-hypovolemic | Do not list | Complete | ||
| Esbriet | Pirfenidone | Idiopathic pulmonary fibrosis | Do not list | Complete | ||
| Aloxi (capsule) | Palonosetron hydrochloride | Chemotherapy-induced nausea and vomiting | Do not list | Complete | ||
| Rebif | Interferon beta-1a | Clinically isolated syndrome | Do not list | Complete |
Last Updated : May 17, 2024